Navigation Links
First of many Neuro-Biotech's licensed products, "SymPath(R) blood test"
Date:10/4/2010

BASEL, Switzerland, Oct. 4 /PRNewswire-FirstCall/ - Neuro-Biotech Corporation (PINKSHEET: MRES)(OTCQB:MRES) Pursuant to the company's press release issued the 30th of September 2010, the following is a brief review and explanation of the earlier statements concerning the first of many Neuro-Biotech's licensed products, "SymPath(R) blood test".

For a better understanding, an "in vitro" blood test is described as, a non evasive test, whereas the testing, as in the case of SymPath(R), is performed on a small amount of the patient's blood. To date the SymPath(R) blood test has been tested on several thousand of patients whose results illustrate a success rate accuracy of 98.8%. The testing audits have been rigorously documented and have met every industry standard.

SymPath(R) is an indispensable tool with unprecedented results. Medical practitioners have long been waiting for a similar test to accurately and quantifiably diagnose those symptoms amongst patients as, depression and stress related disorders. What does this mean for physicians?

Firstly, SymPath(R) assists the medical practitioner in diagnosing patients, based on quantitative measurement, as precise as current cholesterol tests. SymPath(R) allows the medical practitioner to determine with accuracy the severity level of the patient's anxiety or depressive state. The medical practitioner will now be able to state, based on an objective quantified measure, using this test, rather than subjectively determining the diagnosis, as is currently performed.

Furthermore SymPath(R) will eliminate the costly and highly inefficient trial and errors currently performed by physicians in prescribing their recommended remedy, which can waste time and further cause harm for both patients and physicians. For instance, patients suffering from depression or stress related disorders will now properly diagnosed immediately following the testing through Neuro-Biotech's SymPath(R) test.

No more g
'/>"/>

SOURCE Neuro-Biotech Corp.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Kinex Pharmaceuticals announced today that the first ... Cancer Institute. KX2-361 (KX02), a dual src/pre-tubulin ... potent inhibitory activity against a broad panel of brain ... Temozolomide (T98G), the most widely used chemotherapy for the ... mouse model, KX2-361 consistently clears brain tumors after 4 ...
(Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
(Date:12/24/2014)... Dec. 23, 2014 ResMed (NYSE: RMD ... action against Chinese medical device manufacturer BMC Medical Co., Ltd. ... that BMC,s masks listed below infringe ResMed,s patents, and entered ... masks in the United States : ... mask , Willow nasal pillows mask , iVolve ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing ... Chief Technology Officer, will present at the Sidoti & ... on Thursday, November 10, 2011 at 1:20 p.m. ET. ... New York Hotel in New York City. ...
... Nov. 7, 2011 Reportlinker.com ... research report is available in ... Implantable Cardioverter Defibrillators and Cardiac ... Analysis, Competitive Landscape and Market ...
Cached Medicine Technology:Abaxis, Inc. to Present at Sidoti & Company's New York II Emerging Growth Institutional Investor Forum 2Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 2Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 3Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 4Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 5Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 6Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 7Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 8Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 9Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 10Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 11Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 12Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 13Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 14Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 15Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017 16
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
(Date:12/25/2014)... Among early stage breast cancer patients who undergo chemotherapy ... will eventually develop leukemia as a result of their ... from a review of more than 20,000 breast cancer ... that the risk for developing treatment-related leukemia, though low, ... "The frequency of bone marrow cancers such as leukemia ...
(Date:12/25/2014)... tries its best to translate the experience of dress ... introduced its new collection of 2015 prom dresses, and ... prom outfits are guaranteed to contain the perfect designs ... designed for 2015. Anyone who wants to buy ... before Jan. 26, 2015, the deadline of the promotion. ...
(Date:12/25/2014)... December 25, 2014 “ SmileStix ” was ... features the latest and coolest mobile applications on the iOS, ... and host of NewsWatch, conducted the app review and shared ... create personal stickers. , The old saying goes, “A picture ... of words that can describe a single image, because each ...
(Date:12/25/2014)... Newton, North Carolina (PRWEB) December 25, 2014 ... a North Carolina Retirement Community, recently showed their ... and girls of the Catawba County Parenting Network- ... meal, the 10 children gathered around the largest ... community to open presents purchased by residents of ...
Breaking Medicine News(10 mins):Health News:Don't Let Burns Mar Your Holidays 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Retirement Community Residents Make Impact During Holiday Season 2
... ATLANTA - Two drugs approved for use as second line ... frontline therapy for newly diagnosed patients in two clinical trials, ... M. D. Anderson Cancer Center report at the 49th annual ... All patients in both trials have a complete cytogenetic response ...
... PORTLAND, Ore. Gleevec, the targeted cancer pill that has ... with a dire leukemia, as well as preventing disease progression ... , Data at this weekends meeting continues to ... so many, many patients facing cancer, said Brian Druker, M.D., ...
... ALTO, Calif., Dec. 8 Telik, Inc.,(Nasdaq: ... Phase 1,dose-escalation study of TELINTRA(R) (ezatiostat HCl) Tablets ... Phase 2,clinical trials. The data were reported at ... Hematology in Atlanta., The objectives of the ...
... Dec. 8 Data that shed new light ... total,hip replacement, chronic immune thrombocytopenic purpura, and venous,thrombosis ... presented at the 49th Annual Meeting of the ... conference will reveal this new research,on Saturday, December ...
... between mitochondria, memory and socialization , FRIDAY, Dec. ... deficiencies in mitochondria (the source of energy in ... and spatial memory, Japanese researchers report. , The ... between mitochondrial malfunction and mental illness in humans, ...
... a reminder that we must remain vigilant,in protecting women,s ... dedicated health care professionals who provide that care, ... Vicki Saporta, President and CEO of the National Abortion,Federation, ... MD, in Albuquerque,NM:, As the professional association of ...
Cached Medicine News:Health News:Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia 2Health News:Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia 3Health News:Gleevec, the targeted cancer pill, delivers more good news to patients 2Health News:Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome 2Health News:Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome 3Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 2Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 3Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 4Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 5Health News:Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders 6
... helps you deliver unmatched performance through patient-focused ... the most complete anesthesia solution developed, putting ... - at your fingertips., ,The Aisys ... legacy of anesthesia delivery and patient monitoring ...
... Mesh LP is a super-light polypropylene mesh ... body reaction is reduced considerably. Optilene Mesh ... all open hernia repair procedures. It perfectly ... flexibility Optilene Mesh LP adapts to the ...
... Mesh Elastic is a lightweight and large pore ... mesh is able to adapt to all movements ... honeycomb like structure with the large pores enables ... The mesh is ideal for incisional hernia repair ...
... is a lightweight polypropylene mesh which ... reduced,foreign body reaction. The softer, microfilament ... perfectly conforms to,anatomical structures. Due to ... adapts to the movements of the ...
Medicine Products: